Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Karin Hardt, Jeffrey J. Stoddard, Hilde Delanghe et al.|The Lancet Infectious Diseases|2022

Cited by 88